REFERENCES
- Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10 (4): 720–741.
- Malfertheiner P, Megraud F, O'Morain C, et al. European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infec-tion—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16 (2): 167-180.
- Welage LS, Berardi RR. Evaluation of omeprazole, Ian-soprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40 (1): 52–62.
- Midolo PD, Turnidge JD, Lambert JR. Bactericidal activ-ity and synergy studies of proton pump inhibitors and antibi-otics against Helicobacter pylori in vitro. J Antimicrob Chemother 1997; 39 (3): 331–337.
- Gatta L, Perna F, Figura N et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003; 51 (2): 439-442.
- Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44 (2): 458–461.
- Perez-Perez GI. Accurate diagnosis of Helicobacter pylori. Culture, including transport. Gastroenterol Clin North Am 2000;29 (4): 879–84.
- National Committee for Clinical Laboratory Standards. 1998. Standards for testing Helicobacter pylori 1998; M7-A4: 98-103.
- Sjostrom JE, Kuhler T, Larsson H. Basis for the selec-tive antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 1997; 41 (8): 1797–1801.
- Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19 (1): 113–122.